Musculoskeletal diseases: A strategy that has been proposed to treat musculoskeletal diseases via the WNT pathway is to develop inhibitors for WNT antagonists that are relevant to bone development, mainly DKK1 and sclerostin [269]. This evidence concerns the gene DKK1 and musculoskeletal system disorder.